Brenton S Bauer, MD
Cardiovascular Disease (Cardiology) · Torrance
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
- Since medical school
- 14 years
- Graduated 2012
Offices
4 locations · Torrance Memorial Medical Center · Cor Healthcare Medical Associates · Southern California Hospitalist Network Medical Group Inc · Torrance Health Association Inc
Looking this up.
Hospitals listed: Providence Little Company of Mary Med Ctr Torrance · Providence Little Co of Mary Med Ctr San Pedro · Torrance Memorial Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bauer’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A127180 · Current
Licensed to practise in California · since 2013 · expires 2027-09-30 · David Geffen School of Medicine at UCLA.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Little Co of Mary Med Ctr San PedroSan Pedro, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency departmentPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Providence Little Company of Mary Med Ctr TorranceTorrance, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.472, Oct 2024 – Sep 2025
- Torrance Memorial Medical CenterTorrance, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 82% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.36 (1.11 to 1.61), Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 15.79 (10.51 to 21.07) · 1,494 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.21 (0.72 to 1.71) · 9,154 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.328, Oct 2024 – Sep 2025
See every measure and the patient survey for Providence Little Co of Mary Med Ctr San Pedro
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 2 the same, 0 worse of 3 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.08) · 260 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.45 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.3 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.2 · 86 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.8 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.2 · 46 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 844 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 1,991 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,930 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.21 (0.68 to 5.75) · 195 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.6 (0.89 to 4.31) · 181 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.82 (0 to 18.7) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.05 (0.78 to 9.31) · 47 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 53 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 1.36) · 1,620 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 28 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 170 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.2 · 103 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.6 · 126 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 182 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 25 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.3 to 17.3) · 120 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 56 cases | No different | Jan 2024 – Dec 2024 |
What patients said (414 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Providence Little Company of Mary Med Ctr Torrance
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.472 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.09 (0.11 to 2.07) · 1,022 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.59 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 129.31 (75.73 to 182.88) · 65 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 353 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 361 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 495 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 3,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 5,786 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 5,832 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.21 (2.1 to 6.32) · 1,135 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.81 (0.22 to 3.4) · 375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.8 to 3.86) · 1,086 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.78 (2.28 to 15.28) · 389 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.58 (1.19 to 7.98) · 377 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2 (0.51 to 3.49) · 247 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 0.93) · 4,918 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.892 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.225 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.363 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 283 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 709 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.5 · 149 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 428 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.8 · 369 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 551 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 59 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (8.9 to 15.5) · 642 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 331 cases | No different | Jan 2024 – Dec 2024 |
What patients said (414 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Torrance Memorial Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.36 (1.11 to 1.61) | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 15.79 (10.51 to 21.07) · 1,494 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.21 (0.72 to 1.71) · 9,154 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.328 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.72) · 2,154 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.72 (128.91 to 214.54) · 121 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8 · 136 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 176 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.8 · 766 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 806 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 608 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 7,587 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.28 (0.1 to 0.47) · 11,109 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.03 to 0.39) · 11,330 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.13 (2.41 to 5.85) · 2,964 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0.13 to 3.16) · 1,513 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.66 (1.3 to 4.01) · 2,802 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.24 (2.35 to 8.14) · 1,479 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.11 to 2.98) · 650 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2 · 962 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.023 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.646 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.259 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.658 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 1,578 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 21.1 · 183 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.5 · 900 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.9 · 800 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.1 · 1,223 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.3) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7 to 15) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 928 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 316 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.5 to 16.1) · 624 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 781 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,607 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$244,640
Medicare paid this office $244,640 for 2,309 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 401 | $38,347 | $70 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 40 | $21,540 | $41 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 43 | $20,865 | $52 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 42 | $18,161 | $43 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 266 | $15,923 | $55 |
See all 42 services
| Return visit (30+ min) | 401 | $38,347 | $70 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 40 | $21,540 | $41 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 43 | $20,865 | $52 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 42 | $18,161 | $43 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 266 | $15,923 | $55 |
| Return visit (30+ min) | 126 | $14,389 | $88 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,391 | $10,920 | $6 |
| Long return visit (40+ min) | 74 | $10,683 | $117 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 166 | $10,085 | $60 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 38 | $7,889 | $41 |
| New patient visit (45+ min) | 73 | $7,000 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $6,935 | $96 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 22 | $6,612 | $34 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $6,274 | $143 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 86 | $6,127 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $5,393 | $65 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 60 | $3,584 | $60 |
| Ultrasound of heart with probe in esophagus, with report | 41 | $3,567 | $83 |
| New patient visit (60+ min) | 18 | $2,698 | $150 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 181 | $2,579 | $14 |
| Long return visit (40+ min) | 16 | $2,432 | $128 |
| Nuclear medicine study of heart muscle blood flow by pet | 86 | $2,031 | $24 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 62 | $1,963 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 163 | $1,827 | $11 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $1,691 | $81 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 79 | $1,284 | $16 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,264 | $97 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 64 | $891 | $14 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 13 | $790 | $61 |
| Heart muscle strain imaging | 46 | $627 | $9 |
| Ultrasound of heart blood flow, valves and chambers | 40 | $596 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 30 | $503 | $17 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $439 | $21 |
| Ultrasound of heart, follow-up | 17 | $390 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 30 | $331 | $11 |
| Ultrasound of heart, follow-up | 14 | $326 | $20 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 14 | $284 | $19 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 16 | $257 | $14 |
| 3d radiographic procedure | 33 | $257 | $8 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $174 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 41 | $106 | $2 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 13 | $30 | $2 |
Who their Medicare patients are
2,309 Original Medicare patients in 2024. Average age 78 · Under 65 6% · 85 and older 25% · Women 54% · Also on Medicaid 22% · Health risk score 2.03. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 44% · Diabetes 41% · Chronic kidney disease 41% · Heart failure 37% · Atrial fibrillation 35% · Depression 25% · Cancer 24% · COPD 19% · Dementia 17% · Stroke 17%.
The office billed $755,336, Medicare allowed $323,412 and paid $244,640; for 6,416 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 2,309 | 6,416 | 78 | 2.03 | $755,336 | $244,640 |
| 2023 | 1,690 | 5,450 | 77 | 1.99 | $689,320 | $225,242 |
| 2022 | 1,844 | 5,523 | 77 | 2.02 | $674,710 | $227,123 |
| 2021 | 1,564 | 4,226 | 77 | 2.00 | $491,694 | $171,774 |
| 2020 | 1,448 | 3,032 | 77 | 2.21 | $358,518 | $107,543 |
| 2019 | 420 | 736 | 77 | 1.75 | $112,743 | $35,210 |
| 2016 | 34 | 98 | 71 | 3.35 | $33,844 | $7,867 |
| 2015 | 45 | 131 | 73 | 2.42 | $44,679 | $11,408 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 41 services
| Return visit (30+ min) | 389 | $46,035 | $74 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 51 | $22,158 | $45 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 49 | $22,125 | $53 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 47 | $17,656 | $42 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 38 | $9,794 | $41 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 158 | $9,423 | $54 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 157 | $9,377 | $57 |
| Return visit (30+ min) | 99 | $9,014 | $76 |
| New patient visit (45+ min) | 81 | $8,394 | $104 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 32 | $7,258 | $34 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 833 | $6,543 | $7 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 106 | $6,472 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $5,900 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,885 | $100 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 58 | $4,277 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $3,899 | $144 |
| Critical care, first 30-74 minutes | 11 | $3,359 | $177 |
| Ultrasound of heart with probe in esophagus, with report | 39 | $3,223 | $81 |
| Long return visit (40+ min) | 26 | $3,061 | $118 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 123 | $2,046 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 178 | $2,029 | $11 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,741 | $109 |
| New patient visit (45+ min) | 13 | $1,702 | $131 |
| Short return visit (20+ min) | 34 | $1,502 | $42 |
| Nuclear medicine study of heart muscle blood flow by pet | 58 | $1,420 | $24 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,140 | $67 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 36 | $1,139 | $30 |
| Heart muscle strain imaging | 67 | $768 | $9 |
| New patient visit (30+ min) | 13 | $691 | $53 |
| 3d radiographic procedure | 65 | $477 | $7 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 21 | $432 | $20 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 21 | $324 | $15 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 14 | $303 | $22 |
| Ultrasound of heart, follow-up | 13 | $270 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 19 | $267 | $14 |
| 3d radiographic procedure | 32 | $253 | $8 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 17 | $248 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 38 | $228 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 17 | $163 | $10 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 20 | $119 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 39 | $98 | $2 |
2022: 35 services
| Return visit (30+ min) | 282 | $34,860 | $75 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 64 | $29,992 | $54 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 56 | $27,526 | $50 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 56 | $21,405 | $43 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 220 | $13,698 | $57 |
| Return visit (30+ min) | 122 | $12,296 | $75 |
| New patient visit (45+ min) | 92 | $9,880 | $107 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,082 | $9,036 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 102 | $6,837 | $66 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 34 | $6,787 | $35 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $5,882 | $58 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 76 | $4,530 | $60 |
| Short return visit (20+ min) | 71 | $4,079 | $48 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,975 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,843 | $167 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 35 | $3,567 | $42 |
| Ultrasound of heart with probe in esophagus, with report | 34 | $3,314 | $92 |
| Critical care, first 30-74 minutes | 13 | $3,286 | $183 |
| New patient visit (30+ min) | 44 | $2,841 | $65 |
| New patient visit (45+ min) | 25 | $2,548 | $102 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,399 | $109 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 97 | $1,666 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 97 | $1,115 | $11 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $933 | $67 |
| Short return visit (20+ min) | 18 | $765 | $42 |
| Heart muscle strain imaging | 55 | $733 | $10 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 35 | $639 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 35 | $431 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 61 | $415 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 26 | $387 | $15 |
| Ultrasound of heart blood flow, valves and chambers | 17 | $261 | $15 |
| 3d radiographic procedure | 27 | $230 | $8 |
| 3d radiographic procedure | 16 | $131 | $8 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 18 | $116 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 34 | $95 | $3 |
2021: 38 services
| Return visit (30+ min) | 228 | $26,709 | $78 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 54 | $20,153 | $59 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 81 | $16,146 | $35 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 51 | $13,476 | $45 |
| Return visit (30+ min) | 107 | $10,144 | $77 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 152 | $9,602 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 861 | $7,571 | $7 |
| New patient visit (45+ min) | 58 | $6,659 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 54 | $6,342 | $61 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 98 | $5,807 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,324 | $161 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 78 | $4,690 | $59 |
| Critical care, first 30-74 minutes | 11 | $3,921 | $187 |
| New patient visit (45+ min) | 27 | $3,359 | $124 |
| Ultrasound of heart with probe in esophagus, with report | 35 | $3,342 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,002 | $88 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 24 | $2,811 | $36 |
| Telephone medical discussion with physician, 21-30 minutes | 34 | $2,590 | $72 |
| Long return visit (40+ min) | 17 | $2,131 | $118 |
| Short return visit (20+ min) | 40 | $1,913 | $46 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 108 | $1,890 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 108 | $1,287 | $12 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,161 | $106 |
| New patient visit (30+ min) | 14 | $969 | $69 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 45 | $770 | $17 |
| Short return visit (20+ min) | 13 | $729 | $52 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $680 | $43 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 25 | $438 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 54 | $395 | $7 |
| Heart muscle strain imaging | 30 | $363 | $10 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 25 | $293 | $12 |
| Ultrasound of heart, follow-up | 11 | $262 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $249 | $16 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 18 | $249 | $14 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 11 | $245 | $22 |
| 3d radiographic procedure | 23 | $192 | $8 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 21 | $125 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 35 | $97 | $3 |
2020: 32 services
| Return visit (30+ min) | 149 | $10,934 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $9,126 | $172 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 872 | $7,862 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $7,467 | $62 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 103 | $6,287 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 97 | $6,244 | $64 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 97 | $6,214 | $64 |
| Return visit (30+ min) | 89 | $6,175 | $58 |
| Short return visit (20+ min) | 121 | $5,714 | $39 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $4,949 | $90 |
| Short return visit (20+ min) | 94 | $4,374 | $40 |
| Ultrasound of heart with probe in esophagus, with report | 42 | $4,207 | $96 |
| New patient visit (45+ min) | 43 | $4,037 | $94 |
| Critical care, first 30-74 minutes | 11 | $3,788 | $180 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 117 | $2,052 | $17 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $1,786 | $69 |
| New patient visit (30+ min) | 26 | $1,570 | $60 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 117 | $1,417 | $12 |
| New patient visit (45+ min) | 13 | $1,207 | $93 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $1,168 | $69 |
| New patient visit (30+ min) | 13 | $853 | $66 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 26 | $601 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 28 | $522 | $19 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $489 | $44 |
| Ultrasound of heart, follow-up | 17 | $367 | $18 |
| Ultrasound of heart blood flow, valves and chambers | 22 | $366 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 28 | $349 | $12 |
| Ultrasound of heart, follow-up | 13 | $336 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 41 | $297 | $7 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 20 | $135 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 42 | $122 | $3 |
| 3d radiographic procedure | 13 | $112 | $9 |
2019: 16 services
| Return visit (30+ min) | 84 | $6,053 | $67 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 48 | $3,295 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,189 | $63 |
| Return visit (30+ min) | 41 | $2,928 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,753 | $172 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 33 | $2,043 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 24 | $1,532 | $64 |
| New patient visit (45+ min) | 11 | $1,218 | $111 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,140 | $95 |
| Short return visit (20+ min) | 25 | $1,099 | $44 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 56 | $1,080 | $19 |
| Short return visit (20+ min) | 20 | $923 | $44 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 56 | $722 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 93 | $709 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 27 | $197 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $33 | $3 |
2016: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $4,715 | $86 |
2015: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $6,034 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,075 | $173 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,198 | $92 |
| Short return visit (20+ min) | 12 | $665 | $42 |
Medicaid work
$8,076 in 2024
Medicaid paid $8,076 for 1,125 billed services this clinician did in 2024, up to 132 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,125 | $8,076 |
| 2024 | 1,125 | 1 | 132 | $8,076 |
| 2023 | 846 | 1 | 162 | $7,842 |
| 2022 | 821 | 2 | 164 | $7,568 |
| 2021 | 522 | 1 | 140 | $4,613 |
| 2020 | 313 | 1 | 76 | $2,532 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 846 | $7,842 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 808 | $6,978 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 13 | $590 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 522 | $4,613 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 313 | $2,532 |
Drugs they prescribed that Part D paid
$2,272,462
Pharmacies billed $2,272,462 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 5,151) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,932 generic and 1,219 brand-name prescriptions · $2,272,462 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyndamax | 28 | $683,096 | $24,396 |
| Eliquis | 395 | $507,355 | $1,284 |
| Jardiance | 243 | $248,256 | $1,022 |
| Camzyos | 31 | $225,252 | $7,266 |
| Xarelto | 146 | $192,387 | $1,318 |
See all 57 drugs
| Vyndamax | 28 | $683,096 | $24,396 |
| Eliquis | 395 | $507,355 | $1,284 |
| Jardiance | 243 | $248,256 | $1,022 |
| Camzyos | 31 | $225,252 | $7,266 |
| Xarelto | 146 | $192,387 | $1,318 |
| Entresto | 138 | $172,168 | $1,248 |
| Farxiga | 75 | $65,936 | $879 |
| Repatha Sureclick | 21 | $25,559 | $1,217 |
| Ozempic | 14 | $13,823 | $987 |
| Brilinta | 11 | $12,216 | $1,111 |
| Mounjaro | 12 | $10,679 | $890 |
| Metoprolol | 384 | $7,275 | $19 |
| Telmisartan | 132 | $4,431 | $34 |
| Rosuvastatin | 287 | $4,386 | $15 |
| Atorvastatin | 390 | $3,660 | $9 |
| Valsartan | 80 | $3,356 | $42 |
| Ezetimibe | 97 | $3,254 | $34 |
| Potassium Chloride | 52 | $2,582 | $50 |
| Flecainide Acetate | 47 | $2,496 | $53 |
| Ranolazine Er | 17 | $2,277 | $134 |
| Carvedilol | 204 | $2,171 | $11 |
| Losartan | 142 | $2,094 | $15 |
| Amiodarone | 51 | $1,979 | $39 |
| Olmesartan Medoxomil | 64 | $1,945 | $30 |
| Amlodipine Besylate | 299 | $1,886 | $6 |
| Digoxin | 53 | $1,642 | $31 |
| Clopidogrel | 134 | $1,476 | $11 |
| Omega-3 Acid Ethyl Esters | 12 | $1,421 | $118 |
| Furosemide | 200 | $1,241 | $6 |
| Spironolactone | 136 | $1,187 | $9 |
| Telmisartan-Hydrochlorothiazid | 11 | $1,166 | $106 |
| Diltiazem 24hr Er (Xr) | 22 | $1,164 | $53 |
| Nifedipine Er | 27 | $1,134 | $42 |
| Isosorbide Mononitrate Er | 50 | $1,059 | $21 |
| Hydralazine | 58 | $1,048 | $18 |
| Nebivolol | 21 | $982 | $47 |
| Pravastatin | 50 | $965 | $19 |
| Midodrine | 14 | $871 | $62 |
| Lisinopril | 149 | $826 | $6 |
| Diltiazem | 32 | $724 | $23 |
| Isosorbide Dinitrate | 21 | $540 | $26 |
| Sotalol | 22 | $506 | $23 |
| Metoprolol | 104 | $453 | $4 |
| Diltiazem 24hr Er (Cd) | 24 | $417 | $17 |
| Hydrochlorothiazide | 104 | $392 | $4 |
| Nitroglycerin | 40 | $384 | $10 |
| Irbesartan | 17 | $344 | $20 |
| Warfarin | 16 | $321 | $20 |
| Benazepril | 19 | $308 | $16 |
| Ramipril | 18 | $293 | $16 |
| Atenolol | 37 | $248 | $7 |
| Verapamil Er | 16 | $241 | $15 |
| Torsemide | 11 | $194 | $18 |
| Simvastatin | 26 | $190 | $7 |
| Allopurinol | 12 | $120 | $10 |
| Metformin Hcl Er | 12 | $77 | $6 |
| Enalapril Maleate | 11 | $14 | $1 |
Year by year
| 2024 | 5,151 | 664 | 0% (0) | 24% | $2,272,462 |
| 2023 | 5,122 | 664 | 0% (0) | 22% | $2,117,866 |
| 2022 | 5,014 | 634 | 0% (0) | 21% | $1,315,887 |
| 2021 | 4,562 | 588 | 0% (0) | 21% | $1,105,550 |
| 2020 | 3,078 | 502 | None | None | $560,004 |
| 2019 | 469 | 202 | 0% (0) | 19% | $66,074 |
| 2018 | 46 | 20 | 0% (0) | None | $3,910 |
| 2017 | 35 | None | 0% (0) | None | $2,473 |
| 2016 | 161 | 34 | None | None | $10,272 |
| 2015 | 120 | 31 | None | None | $9,093 |
| 2014 | 55 | 18 | 20% (11) | None | $3,939 |
| 2013 | 16 | None | 0% (0) | None | $705 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 53 drugs
| Vyndamax | 29 | $816,675 | $28,161 |
| Eliquis | 389 | $448,406 | $1,153 |
| Xarelto | 173 | $231,102 | $1,336 |
| Entresto | 123 | $165,530 | $1,346 |
| Jardiance | 133 | $119,759 | $900 |
| Farxiga | 104 | $92,202 | $887 |
| Brilinta | 18 | $16,953 | $942 |
| Repatha Sureclick | 12 | $15,559 | $1,297 |
| Metoprolol | 391 | $9,902 | $25 |
| Telmisartan | 126 | $6,288 | $50 |
| Rosuvastatin | 235 | $6,179 | $26 |
| Atorvastatin | 400 | $5,968 | $15 |
| Ezetimibe | 76 | $4,922 | $65 |
| Valsartan | 72 | $4,542 | $63 |
| Amiodarone | 50 | $4,509 | $90 |
| Bystolic | 11 | $3,923 | $357 |
| Olmesartan Medoxomil | 68 | $3,882 | $57 |
| Carvedilol | 238 | $3,193 | $13 |
| Losartan | 163 | $3,058 | $19 |
| Amlodipine Besylate | 353 | $2,943 | $8 |
| Flecainide Acetate | 53 | $2,513 | $47 |
| Clopidogrel | 140 | $2,313 | $17 |
| Ranolazine Er | 20 | $2,238 | $112 |
| Digoxin | 44 | $2,021 | $46 |
| Nifedipine Er | 35 | $2,001 | $57 |
| Isosorbide Mononitrate Er | 73 | $1,874 | $26 |
| Diltiazem 24hr Er (Xr) | 28 | $1,838 | $66 |
| Telmisartan-Hydrochlorothiazid | 13 | $1,790 | $138 |
| Sotalol | 31 | $1,552 | $50 |
| Potassium Chloride | 38 | $1,549 | $41 |
| Hydralazine | 54 | $1,537 | $28 |
| Furosemide | 223 | $1,518 | $7 |
| Pravastatin | 48 | $1,309 | $27 |
| Lisinopril | 148 | $1,277 | $9 |
| Spironolactone | 132 | $1,156 | $9 |
| Nebivolol | 12 | $1,036 | $86 |
| Metoprolol | 128 | $912 | $7 |
| Nitroglycerin | 35 | $712 | $20 |
| Irbesartan | 16 | $695 | $43 |
| Bumetanide | 13 | $668 | $51 |
| Diltiazem | 36 | $666 | $19 |
| Simvastatin | 41 | $618 | $15 |
| Diltiazem 24hr Er (Cd) | 28 | $580 | $21 |
| Hydrochlorothiazide | 112 | $568 | $5 |
| Metolazone | 16 | $355 | $22 |
| Ramipril | 22 | $334 | $15 |
| Propranolol | 12 | $306 | $25 |
| Atenolol | 39 | $292 | $7 |
| Allopurinol | 13 | $265 | $20 |
| Torsemide | 14 | $254 | $18 |
| Warfarin | 14 | $220 | $16 |
| Clonidine | 12 | $149 | $12 |
| Amoxicillin | 12 | $24 | $2 |
2022: 56 drugs
| Eliquis | 362 | $405,616 | $1,120 |
| Vyndamax | 11 | $226,542 | $20,595 |
| Xarelto | 179 | $204,452 | $1,142 |
| Entresto | 169 | $170,789 | $1,011 |
| Farxiga | 121 | $84,834 | $701 |
| Jardiance | 42 | $32,172 | $766 |
| Repatha Sureclick | 34 | $25,959 | $764 |
| Brilinta | 18 | $20,386 | $1,133 |
| Rosuvastatin | 214 | $13,024 | $61 |
| Vascepa | 19 | $9,260 | $487 |
| Metoprolol | 396 | $9,239 | $23 |
| Telmisartan | 118 | $5,754 | $49 |
| Atorvastatin | 342 | $5,513 | $16 |
| Ezetimibe | 67 | $4,641 | $69 |
| Olmesartan Medoxomil | 74 | $4,173 | $56 |
| Flecainide Acetate | 67 | $3,848 | $57 |
| Bystolic | 11 | $3,508 | $319 |
| Carvedilol | 278 | $3,112 | $11 |
| Nifedipine Er | 37 | $2,776 | $75 |
| Valsartan | 44 | $2,384 | $54 |
| Clopidogrel | 139 | $2,358 | $17 |
| Amlodipine Besylate | 341 | $2,321 | $7 |
| Potassium Chloride | 46 | $2,200 | $48 |
| Amiodarone | 61 | $1,987 | $33 |
| Eplerenone | 14 | $1,922 | $137 |
| Omega-3 Acid Ethyl Esters | 13 | $1,786 | $137 |
| Digoxin | 43 | $1,715 | $40 |
| Furosemide | 253 | $1,705 | $7 |
| Hydralazine | 62 | $1,620 | $26 |
| Isosorbide Mononitrate Er | 92 | $1,614 | $18 |
| Diltiazem 24hr Er (Xr) | 25 | $1,605 | $64 |
| Losartan | 124 | $1,572 | $13 |
| Spironolactone | 149 | $1,500 | $10 |
| Nebivolol | 17 | $1,444 | $85 |
| Pravastatin | 52 | $1,155 | $22 |
| Metoprolol | 120 | $986 | $8 |
| Nitroglycerin | 39 | $897 | $23 |
| Lisinopril | 130 | $871 | $7 |
| Sotalol | 27 | $780 | $29 |
| Diltiazem 24hr Er (Cd) | 25 | $667 | $27 |
| Amlodipine-Olmesartan | 11 | $660 | $60 |
| Diltiazem 24hr Er | 11 | $629 | $57 |
| Metolazone | 18 | $557 | $31 |
| Simvastatin | 50 | $508 | $10 |
| Hydrochlorothiazide | 85 | $463 | $5 |
| Benazepril | 12 | $457 | $38 |
| Propranolol | 12 | $447 | $37 |
| Diltiazem | 24 | $405 | $17 |
| Ramipril | 22 | $333 | $15 |
| Atenolol | 44 | $320 | $7 |
| Allopurinol | 11 | $265 | $24 |
| Klor-Con M20 | 13 | $261 | $20 |
| Torsemide | 14 | $258 | $18 |
| Clonidine | 12 | $245 | $20 |
| Chlorthalidone | 13 | $213 | $16 |
| Warfarin | 16 | $143 | $9 |
2021: 56 drugs
| Eliquis | 268 | $280,592 | $1,047 |
| Vyndamax | 12 | $233,555 | $19,463 |
| Xarelto | 205 | $214,948 | $1,049 |
| Entresto | 139 | $125,784 | $905 |
| Farxiga | 40 | $29,198 | $730 |
| Brilinta | 31 | $29,038 | $937 |
| Repatha Sureclick | 47 | $27,732 | $590 |
| Jardiance | 16 | $14,824 | $926 |
| Rosuvastatin | 180 | $11,634 | $65 |
| Metoprolol | 378 | $8,740 | $23 |
| Bystolic | 25 | $7,807 | $312 |
| Telmisartan | 95 | $6,570 | $69 |
| Vascepa | 17 | $6,112 | $360 |
| Atorvastatin | 330 | $5,885 | $18 |
| Ezetimibe | 72 | $5,039 | $70 |
| Olmesartan Medoxomil | 65 | $3,864 | $59 |
| Omega-3 Acid Ethyl Esters | 18 | $3,204 | $178 |
| Flecainide Acetate | 55 | $3,157 | $57 |
| Valsartan | 26 | $2,847 | $110 |
| Carvedilol | 241 | $2,511 | $10 |
| Olmesartan-Amlodipine-Hctz | 13 | $2,496 | $192 |
| Potassium Chloride | 56 | $2,416 | $43 |
| Losartan | 149 | $2,232 | $15 |
| Digoxin | 53 | $2,145 | $40 |
| Isosorbide Mononitrate Er | 99 | $2,080 | $21 |
| Clopidogrel | 123 | $2,064 | $17 |
| Amlodipine Besylate | 278 | $2,039 | $7 |
| Propafenone | 12 | $1,987 | $166 |
| Furosemide | 250 | $1,696 | $7 |
| Diltiazem 24hr Er | 17 | $1,492 | $88 |
| Nifedipine Er | 27 | $1,474 | $55 |
| Spironolactone | 131 | $1,312 | $10 |
| Hydralazine | 44 | $1,052 | $24 |
| Pravastatin | 48 | $1,048 | $22 |
| Sotalol | 25 | $844 | $34 |
| Diltiazem 24hr Er (Cd) | 27 | $811 | $30 |
| Simvastatin | 66 | $766 | $12 |
| Metoprolol | 100 | $622 | $6 |
| Irbesartan | 15 | $618 | $41 |
| Lisinopril | 100 | $614 | $6 |
| Chlorthalidone | 22 | $588 | $27 |
| Amiodarone | 40 | $558 | $14 |
| Nitroglycerin | 26 | $539 | $21 |
| Hydrochlorothiazide | 78 | $501 | $6 |
| Enalapril Maleate | 13 | $463 | $36 |
| Felodipine Er | 14 | $391 | $28 |
| Warfarin | 24 | $367 | $15 |
| Amlodipine-Olmesartan | 11 | $339 | $31 |
| Benazepril | 11 | $320 | $29 |
| Ramipril | 19 | $266 | $14 |
| Clonidine | 16 | $247 | $15 |
| Quinapril | 15 | $223 | $15 |
| Atenolol | 34 | $207 | $6 |
| Torsemide | 22 | $203 | $9 |
| Klor-Con 10 | 11 | $181 | $16 |
| Omeprazole | 11 | $65 | $6 |
2020: 44 drugs
| Eliquis | 205 | $197,197 | $962 |
| Xarelto | 120 | $116,002 | $967 |
| Entresto | 108 | $106,742 | $988 |
| Brilinta | 15 | $14,490 | $966 |
| Rosuvastatin | 143 | $13,643 | $95 |
| Jardiance | 12 | $11,388 | $949 |
| Metoprolol | 290 | $9,546 | $33 |
| Bystolic | 11 | $5,130 | $466 |
| Vascepa | 15 | $5,090 | $339 |
| Atorvastatin | 240 | $4,549 | $19 |
| Telmisartan | 53 | $4,411 | $83 |
| Flecainide Acetate | 56 | $3,992 | $71 |
| Olmesartan Medoxomil | 47 | $3,630 | $77 |
| Ezetimibe | 37 | $2,707 | $73 |
| Amlodipine Besylate | 196 | $2,038 | $10 |
| Carvedilol | 172 | $1,830 | $11 |
| Losartan | 113 | $1,824 | $16 |
| Potassium Chloride | 36 | $1,760 | $49 |
| Digoxin | 35 | $1,531 | $44 |
| Isosorbide Mononitrate Er | 45 | $1,299 | $29 |
| Diltiazem 24hr Er (Cd) | 38 | $1,196 | $31 |
| Dilt-Xr | 14 | $1,175 | $84 |
| Clopidogrel | 76 | $1,028 | $14 |
| Pravastatin | 30 | $990 | $33 |
| Chlorthalidone | 20 | $950 | $47 |
| Furosemide | 146 | $858 | $6 |
| Irbesartan | 17 | $781 | $46 |
| Spironolactone | 80 | $745 | $9 |
| Simvastatin | 53 | $623 | $12 |
| Lisinopril | 73 | $556 | $8 |
| Hydralazine | 29 | $540 | $19 |
| Sotalol | 13 | $512 | $39 |
| Amiodarone | 25 | $431 | $17 |
| Metoprolol | 62 | $428 | $7 |
| Metolazone | 11 | $396 | $36 |
| Benazepril | 29 | $360 | $12 |
| Warfarin | 24 | $335 | $14 |
| Hydrochlorothiazide | 48 | $302 | $6 |
| Nitroglycerin | 14 | $248 | $18 |
| Ramipril | 14 | $202 | $14 |
| Torsemide | 16 | $202 | $13 |
| Tamsulosin | 11 | $175 | $16 |
| Atenolol | 22 | $169 | $8 |
| Clonidine | 12 | $118 | $10 |
2019: 12 drugs
| Eliquis | 22 | $19,174 | $872 |
| Xarelto | 13 | $14,799 | $1,138 |
| Entresto | 15 | $11,359 | $757 |
| Metoprolol | 46 | $1,834 | $40 |
| Olmesartan Medoxomil | 17 | $1,792 | $105 |
| Rosuvastatin | 20 | $1,741 | $87 |
| Atorvastatin | 46 | $1,023 | $22 |
| Carvedilol | 32 | $427 | $13 |
| Amlodipine Besylate | 38 | $351 | $9 |
| Losartan | 19 | $301 | $16 |
| Furosemide | 19 | $133 | $7 |
| Lisinopril | 16 | $106 | $7 |
2016: 2 drugs
| Atorvastatin | 15 | $362 | $24 |
| Metformin | 14 | $79 | $6 |
2015: 1 drug
| Lisinopril | 11 | $68 | $6 |
Money from drug and device companies
$5,435 in 2025
| 2025 | 10 | 35 | $4,800 | $5,435 |
| 2024 | 11 | 20 | None | $592 |
| 2023 | 6 | 7 | None | $147 |
| 2022 | 5 | 7 | None | $98 |
| 2021 | 1 | 2 | None | $49 |
| 2020 | 5 | 6 | None | $109 |
| 2019 | 3 | 6 | None | $94 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Camzyos | $4,931 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $172 | 7 payments
|
| Novartis Pharmaceuticals | Leqvio | $67 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $66 | 5 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $58 | 2 payments
|
| BridgeBio Pharma | Attruby | $40 | 2 payments
|
See all 34 published payments
| Alnylam Pharmaceuticals | Meals · 2025-12-19 | Amvuttra | $34 |
| BridgeBio Pharma | Meals · 2025-12-18 | Attruby | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-12 | Camzyos | $5 |
| Novartis Pharmaceuticals | Meals · 2025-10-24 | Leqvio | $19 |
| Alnylam Pharmaceuticals | Meals · 2025-10-10 | Amvuttra | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-03 | Camzyos | $4 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-03 | Camzyos | $28 |
| BridgeBio Pharma | Meals · 2025-09-23 | Attruby | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-18 | Camzyos | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-12 | Camzyos | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-12 | Wainua | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-28 | Jardiance | $24 |
| Novartis Pharmaceuticals | Meals · 2025-08-22 | Leqvio | $14 |
| Novartis Pharmaceuticals | Meals · 2025-08-22 | Leqvio | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-01 | Eliquis | $21 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-25 | Lifevest | $8 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-25 | Jardiance | $16 |
| Kestra Medical Technology Services | Meals · 2025-07-10 | Assure Wcd | $14 |
| Pfizer | Meals · 2025-07-02 | Vyndaqel | $21 |
| Novartis Pharmaceuticals | Meals · 2025-06-20 | Leqvio | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-13 | Jardiance | $24 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-06-11 | Lifevest | $8 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-05-15 | Lifevest | $21 |
| Pfizer | Meals · 2025-04-29 | Vyndaqel | $18 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-18 | Jardiance | $26 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-11 | Jardiance | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-07 | Camzyos | $23 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-03-05 | Lifevest | $4 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-28 | Jardiance | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-24 | Camzyos | $9 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-02-20 | Lifevest | $25 |
| Medtronic | Meals · 2025-02-14 | Pulseselect | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-17 | Jardiance | $29 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-01-16 | None | $4,800 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $592
| Abbott Laboratories | Mitraclip | $195 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $77 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $70 | 3 payments
|
| Itamar Medical | Watchpatone | $61 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $58 | 2 payments
|
| Lantheus Medical Imaging | Definity | $36 | 1 payment
|
| Alnylam Pharmaceuticals | Amvuttra | $25 | 1 payment
|
| Pfizer | Vyndaqel | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Wainua | $18 | 1 payment
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $16 | 1 payment
|
| Boston Scientific | Watchman Flx | $16 | 1 payment
|
2023: $147
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $34 | 2 payments
|
| Novartis Pharmaceuticals | Leqvio | $30 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $23 | 1 payment
|
| Abbott Laboratories | Mitraclip | $21 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $19 | 1 payment
|
| Pfizer | Vyndaqel | $19 | 1 payment
|
2022: $98
| Abbott Laboratories | Mitraclip | $32 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $27 | 2 payments
|
| Novo Nordisk | Ozempic | $24 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $12 | 1 payment
|
| Itamar Medical | Watchpat | $3 | 1 payment
|
2021: $49
| Pfizer | Eliquis | $49 | 2 payments
|
2020: $109
| Pfizer | Vyndaqel | $34 | 2 payments
|
| Boston Scientific | Watchman | $22 | 1 payment
|
| Philips Electronics North America | Services and Other | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $17 | 1 payment
|
| Amgen | Repatha | $16 | 1 payment
|
2019: $94
| Pfizer | Eliquis | $60 | 4 payments
|
| Amgen | Repatha | $17 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $16 | 1 payment
|
Professional record
- NPI
- 1992071211
- Licence
- CA A127180California A127180: Current · expires 2027-09-30
- Group
- Torrance Memorial Medical Center · Cor Healthcare Medical Associates · Southern California Hospitalist Network Medical Group Inc · Torrance Health Association Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 5767 W Century Blvd Ste 400, Los Angeles, CA, 90045
- NPI first listed
- 2012-03-30
- NPI last updated
- 2026-04-07
- NPI record certified
- 2026-04-07
This is when the NPI record was last certified, not a medical board exam.